N/A N=129 A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)
Chronic Rhinitis
Primary: Mean Change of the Reflective Total Nasal Symptoms Score (rTNSS) — -4.2 Change in rTNSS score from baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=270 A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
Lennox Gastaut Syndrome (LGS)
Primary: Percent Change From Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days During the Full Treatment Period — -6.69; -6.11 percent change — p==0.785
Phase 2 N=87 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
HER2-amplified Biliary Tract Cancers
Primary: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) — 33; 0 Participants
N/A N=113 Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
Untreated CD30-Positive Hodgkin's Lymphoma
Primary: Percentage of Participants With Grade 3 or Higher Neutropenia and Febrile Neutropenia — 65; 31 Participants
Phase 1 N=18 Influence of Fluvoxamine on the Pharmacokinetics of BI 409306
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5441.83; 175.10 nanomole…
N/A N=70 The Vivaer Procedure for Treatment of the Septal Swell Bodies (SWELL)
Nasal Obstruction
Primary: Nasal Obstruction Symptom Evaluation (NOSE) Scale Mean Change — -45.3 score on a scale
Phase 2 N=62 Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
Allergic Bronchopulmonary Aspergillosis
Primary: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo — 0.002; 0.203 Liters — p=0.0022
N/A N=16 Virtual Training for Latino Caregivers to Manage Symptoms of Dementia
Caregiver Burden · Alzheimer Disease · Dementia
Primary: Change in Baseline Revised Memory and Behavior Problem Checklist Score at 6 Weeks (Overall Caregiver Reaction) — -6.90 units on a scale
N/A N=64 Timing of Repeat Voiding Trials After Outpatient Pelvic Floor Surgery
Pelvic Organ Prolapse · Urinary Incontinence,Stress · Surgery
Primary: Failed Office Voiding Trials — 7; 1 Participants
N/A N=30 Efficacy and Mechanism of rTMS in Children With ASD: an Open-label Clinical Trial(Ⅱ)
Autism Spectrum Disorder
Primary: Social Response Scale (SRS) Scores — 94.27; 81.50; 77.67 score on a scale — p=<0.001
Phase 3 N=276 Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Overactive Bladder
Primary: Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%) — 2; 3; 17; 3 Participants
N/A N=25 Motor Control Physical Therapist Support Stroke
Stroke
Primary: Center of Pressure Path Length — 98.5; 156.1 cm^2
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
Phase 2 N=15 Repeated Neurocognitive Measurements in Depressed Patients
Depression, Unipolar
Primary: fMRI Intrinsic Connectivity: Default Mode Network — 0.40 units on a scale
Phase 3 N=689 Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye — 0.2; -4.2 Letters Read — p=<0.001